Related Experiment Video
Updated: Jul 22, 2026
10:42
Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
Published on: May 13, 2016
Alcoholic cirrhosis-associated immune dysfunction: What does it imply for us?
Mingyu Sun1, Ziyi Yang2, Fei Tang1
1The Third Central Hospital of Tianjin, 83 Jintang Road, Hedong District, Tianjin 300170, China.
Annals of Hepatology
|May 16, 2025
Summary
Alcoholic cirrhosis, driven by alcohol consumption, leads to immune dysfunction. Interventions targeting gut microbiota and immune response may slow disease progression.
Area of Science:
- Hepatology
- Immunology
- Microbiology
Background:
- Alcoholic cirrhosis is a major cause of chronic liver disease, with rising incidence linked to increased alcohol consumption.
- Alcohol metabolism in the gut generates toxic byproducts, increasing intestinal permeability and systemic inflammation.
- This leads to cirrhosis-associated immune dysfunction (CAID), a key factor in disease severity and progression.
Purpose of the Study:
- To review the relationship between alcoholic cirrhosis and CAID.
- To explore potential interventions for mitigating alcoholic cirrhosis by targeting immune response and gut microbiota.
Main Methods:
- This is a narrative review.
- Literature search on alcoholic cirrhosis, gut microbiota, and immune dysfunction.
Main Results:
- Alcohol metabolism disrupts gut microbiota and increases intestinal permeability, causing CAID.
- CAID is linked to cirrhosis severity and can lead to multi-organ failure.
Conclusions:
- Modulating gut microbiota and immune response offers potential therapeutic strategies for alcoholic cirrhosis.
- Targeted interventions may help mitigate the development and progression of alcoholic cirrhosis.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...